Wanna see a trick? Give us any topic and we can tie it back to the economy. At Planet Money, we explore the forces that shape our lives and bring you along for the ride. Don't just understand the economy – understand the world. Wanna go deeper? Subscribe to Planet Money+ and get sponsor-free episodes of Planet Money, The Indicator, and Planet Money Summer School. Plus access to bonus content. It's a new way to support the show you love. Learn more at plus.npr.org/planetmoney
…
continue reading
Content provided by Guy Raz | Wondery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Guy Raz | Wondery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Moderna and Flagship Pioneering: Noubar Afeyan
MP3•Episode home
Manage episode 304298397 series 1324390
Content provided by Guy Raz | Wondery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Guy Raz | Wondery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In the field of bio-tech, it can take 10 years and millions of dollars to see if an experimental idea might turn into a life-saving treatment—if it ever does. Noubar Afeyan fully understood those risks when he co-founded Moderna in 2010. He and his colleagues were looking for a way to deploy the messenger RNA molecule to tackle life-threatening diseases. In January of 2020, an urgent opportunity presented itself in the form of a deadly virus that was spreading across the globe. At a breathtaking pace, Moderna produced a prototype for a COVID-19 vaccine, partnered with the NIH to test it, and produced millions of doses, becoming part of the most rapid vaccine roll-out in human history. While Moderna is the best known of Noubar's companies, he has launched many others in the bio-tech space as part of Flagship Pioneering, his multi-billion dollar venture studio. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
…
continue reading
698 episodes
MP3•Episode home
Manage episode 304298397 series 1324390
Content provided by Guy Raz | Wondery. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Guy Raz | Wondery or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In the field of bio-tech, it can take 10 years and millions of dollars to see if an experimental idea might turn into a life-saving treatment—if it ever does. Noubar Afeyan fully understood those risks when he co-founded Moderna in 2010. He and his colleagues were looking for a way to deploy the messenger RNA molecule to tackle life-threatening diseases. In January of 2020, an urgent opportunity presented itself in the form of a deadly virus that was spreading across the globe. At a breathtaking pace, Moderna produced a prototype for a COVID-19 vaccine, partnered with the NIH to test it, and produced millions of doses, becoming part of the most rapid vaccine roll-out in human history. While Moderna is the best known of Noubar's companies, he has launched many others in the bio-tech space as part of Flagship Pioneering, his multi-billion dollar venture studio. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
…
continue reading
698 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.